Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1589-1596

  Sugishita, Yoshiyuki ^a   Kammori, Makoto ^a   Yamada, Osamu ^b   Poon, Steven S S ^c   Kobayashi, Makio ^d   Onoda, Naoyoshi ^e   Yamazaki, Kazuko ^a   Fukumori, Tatsuya ^a   Yoshikawa, Kei Ichi ^a   Onose, Hiroyuki ^a   Ishii, Shinnya ^a   Yamada, Emiko ^a   Yamada, Tetsu ^a  

^a Kanaji Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Mithuwadai General Hospital   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Differentiated thyroid cancer; Human epidermal growth factor receptor 2 neu; Telomerase; Telomere; Tissue quantitative fluorescence in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTICLE; DIFFERENTIATED THYROID CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR CARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TELOMERE SHORTENING; TISSUE SECTION; TUMOR GENE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL DIFFERENTIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; TELOMERE SHORTENING; THYROID NEOPLASMS;

EID: 84875994768     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1848     Document Type: Article

References (52)

1. Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
2. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986. (Pubitemid 16095607)
3. Salmon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
4. Salmon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
5. Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3: 237-252, 1998.
6. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008. (Pubitemid 351724903)
7. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Shon CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Shon JH, Ryu SH and Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51: 1371-1379, 2006. (Pubitemid 44315804)
8. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M and Ochiai A: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15: 65-71, 2006.
9. Zhag XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y and Huang J: Comparative study on overexpression of her2/neu and her3 in gastric cancer. World J Surg 33: 2112-2118, 2009.
10. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M and Hirohashi S: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72: 3179-3184, 1993. (Pubitemid 23356757)
11. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirano T and Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999. (Pubitemid 29202761)
12. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209, 2000. (Pubitemid 30350211)
13. Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P and García-Muñiz JL: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10: 234-241, 2003. (Pubitemid 40486955)
14. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soni Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K and Isola J: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005. (Pubitemid 40309309)
15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J and Kang YK: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
16. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991. (Pubitemid 21912269)
17. Harley CB, Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460, 1990.
18. Von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci 27: 339-344, 2002. (Pubitemid 34756516)
19. Harly CB and Villeponteau B: Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 5: 249-255, 1995.
20. De Lange T: Telomeres and senescence: ending the debate. Science 279: 334-335, 1998. (Pubitemid 28063358)
21. DePinho RA: The age of cancer. Nature 408: 248-254, 2000.
22. Svenson U and Roos G: Telomere length as a biological marker in malignancy. Biochim Biophys Acta 1792: 317-323, 2009.
23. Wyatt HD, West SC and Beattie TL: InTERTpreting telomerase structure and function. Nucleic Acids Res 38: 5609-5622, 2010.
24. Kammori M, Nakamura K, Hashimoto M, Ogawa T, Kaminishi M and Takubo K: Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization. Int J Oncol 22: 985-991, 2003.
25. Furugori E, Hirayama R, Nakamura K, Kammori M, Esaki Y and Takubo K: Telomere shortening in gastric carcinoma with aging despite telomerase activation. J Cancer Res Clin Oncol 126: 481-485, 2000. (Pubitemid 30483163)
26. Nakamura K, Furugori E, Esaki Y, Arai T, Sawabe M, Okayasu I, Fujiwara M, Kammori M, Mafune K, Kato M, Oshimura M, Sasajima K and Takubo K: Correlation of telomere lengths in normal and cancers tissue in the large bowel. Cancer Lett 158: 179-184, 2000.
27. Kammori M, Takubo K, Nakamura K, Furugouri E, Endo H, Kanauchi H, Mimura Y and Kaminishi M: Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett 159: 175-181, 2000.
28. O'Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, Emond MJ, Gollahon KA, Moskovitz AH, Crispin DA, Potter JD and Rabinovitch PS: Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 32: 280-284, 2002.
29. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, March GE and De Marzo AM: Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 160: 1259-1268, 2002. (Pubitemid 34411630)
30. Kammori M, Kanauchi H, Nakamura K, Kawahara M, Weber TK, Mafune K, Kaminishi M and Takubo K: Demonstration of human telomerase reverse transcriptase in human colorectal carcinomas by in situ hybridization. Int J Oncol 20: 15-21, 2002.
31. Aida J, Izumiyama-Shimomura N, Nakamura K, Ishii A, Ishikawa N, Honma N, Kurabayashi R, Kammori M, Poon SS, Arai T and Takubo K: Telomere length variations in 6 mucosal cell types of gastric tissue observed using a novel quantitative fluorescence in situ hybridization method. Hum Pathol 38: 1192-1200, 2007. (Pubitemid 47058156)
32. Kammori M, Izumiyama N, Nakamura K, Kurabayashi R, Kashio M, Aida J, Poon SS and Kaminishi M: Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology 71: 430-436, 2006. (Pubitemid 47573708)
33. Kawauchi K, Ihjima K and Yamada O: IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 174: 5261-5269, 2005. (Pubitemid 40593164)
34. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H and Kreipe HH: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Vichows Arch 457: 299-307, 2010.
35. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007. (Pubitemid 350003059)
36. Ito Y, Fukushima M, Kihara M, Takamura Y, Kobayashi K, Miya A and Miyauchi A: Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr J 59: 457-464, 2012.
37. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR and Sherman SI: The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97: E878-E887, 2012.
38. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638-2648, 1998. (Pubitemid 29019586)
39. Kurabayashi R, Takubo K, Aida J, Honma N, Poon SS, Kammori M, Izumiyama-Shimomura N, Nakamura K, Tsuji E, Matsuura M, Ogawa T and Kaminishi M: Luminal and cancer cells in the breast show more rapid telomere shortening than myoepithelial cells and fibroblasts. Hum Pathol 39: 1647-1655, 2008.
40. Lal P, Salazar PA, Hudis CA, Ladanyi M and Chen B: HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121: 631-636, 2004. (Pubitemid 38533994)
41. Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T and Takubo K: Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. Oncol Rep 19: 651-656, 2008. (Pubitemid 351330431)
42. Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, Mikuz G and Ensinger C: Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch 442: 322-328, 2003. (Pubitemid 36561088)
43. Mondi MM, Rich R, Ituarte P, Wong M, Bergman S, Clark OH and Perrier ND: HER2 expression in thyroid tumors. Am Surg 69: 1100-1103, 2003. (Pubitemid 44296675)
44. Ensinger C, Prommegger R, Kendler D, Gabriel M, Spizzo G, Mikuz G and Kremser R: Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Anticancer Res 23: 2349-2354, 2003.
45. Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Bockisch A and Otterbach F: Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 44: 179-184, 2005. (Pubitemid 41564502)
46. Mitteldorf CA, Leite KR, Meirelles MI, Gattas GJ and Camara-Lopes LH: Overexpression of HER2/neu oncoprotein in cytologic specimens. Acta Cytol 48: 199-206, 2004. (Pubitemid 38381106)
47. Griffith JK, Bryant JE, Fordyce CA, Gilliland FD, Joste NE and Moyzis RK: Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat 54: 59-64, 1999. (Pubitemid 29209918)
48. Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC and Griffith JK: Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 99: 193-202, 2006. (Pubitemid 44268267)
49. Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN and Griffith JK: Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res 13: 7037-7043, 2007. (Pubitemid 350276885)
50. Donaldson L, Fordyce C, Gilliland F, Smith A, Feddersen R, Joste N, Moyzis R and Griffith J: Association between outcome and telomere DNA content in prostate cancer. J Urol 162: 1788-1792, 1999. (Pubitemid 29474730)
51. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC and Griffith JK: Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 173: 610-614, 2005.
52. Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, Hernando F, López-Asenjo JA, Torres AJ, Benito M and Iniesta P: Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer 60: 416-425, 2008.